Abstract 672P
Background
Open sharing of synthetic trial data could facilitate secondary analyses and synthetic control arm development.
Methods
This study included 128 experimental vs. control treatments for solid tumors from 115 phase 3 randomized clinical trials (RCTs) published in 7 high-impact journals in 2023. Original individual patient data were reconstructed from the published Kaplan-Meier curves of overall survival (OS) in the intention-to-treat population. Either both arms (fully synthetic; retaining original sample size) or only the control arm (partially synthetic; retaining original control arm size) were synthesized using statistical models (Weibull and Synthpop) and a deep generative model (SurvivalGAN). Original and synthetic RCTs were compared through the probability overlap (0: none, 1: perfect) of the 95% confidence intervals (CIs) for the hazard ratio (HR), and the true (TPR) and false positive rate (FPR) with respect to the direction of the HR and its statistical significance on the 0.05 level.
Results
The median sample size was 571 (range 82-5637) and the median HR for OS was 0.80 (range 0.39-1.14) in the original (reconstructed) RCTs. Fifty-six (43.8%) were statistically significant, all of which showing superiority of the experimental treatment. The results presented in the table indicate that the use of synthetic arms may introduce bias due to generative model misspecification (in particular for fully synthetic RCTs created by Weibull) and additional variability inherent to the data generating process (more pronounced in fully vs. partially synthetic RCTs and in deep generative vs. statistical models), leading to insufficient CI overlap for the HR and thereby impacting statistical inference. TPR ranges from 2.6% to 80.4% and 90.9% to 98.2% in fully and partially synthetic RCTs, while FPR ranges from 25.0% to 46.4% and 27.8% to 44.4%, respectively. Table: 672P
Results of the synthetic RCTs
Approach | Model | Difference in log HR: mean (sd) | 95% CI overlap: mean (sd) | TPR: % | FPR: % |
Full | Weibull | 0.33 (0.43) | 0.43 (0.39) | 2.6 | 29.5 |
Full | Synthpop | 0.01 (0.20) | 0.84 (0.20) | 80.4 | 25.0 |
Full | SurvivalGAN | -0.01 (0.73) | 0.46 (0.35) | 66.0 | 46.4 |
Partial | Weibull | -0.11 (0.15) | 0.81 (0.23) | 90.9 | 32.4 |
Partial | Synthpop | -0.10 (0.25) | 0.85 (0.26) | 96.4 | 27.8 |
Partial | SurvivalGAN | -0.14 (0.23) | 0.71 (0.31) | 98.2 | 44.4 |
Conclusions
Naive inference from RCTs with synthetic arms may lead to overly optimistic or even wrong conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ghent University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
671P - LuMIERE: A phase I/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors
Presenter: Jonathan McConathy
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01
682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Presenter: Shigehiro Koganemaru
Session: Poster session 01